Valuation: Palisade Bio, Inc.

Market Cap 363M 315M 295M 270M 509M 34.56B 516M 3.45B 1.35B 17.27B 1.36B 1.33B 57.47B P/E 2026 *
-8.8x
P/E 2027 * -7.43x
Enterprise Value 269M 233M 218M 200M 377M 25.58B 382M 2.55B 1B 12.78B 1.01B 986M 42.55B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.25%
Yield 2026 *
-
Yield 2027 * -
1 day-1.42%
1 week+6.63%
Current month+10.29%
1 month+2.45%
3 months+4.50%
6 months+27.44%
Current year-11.06%
1 week 1.89
Extreme 1.89
2.15
1 month 1.84
Extreme 1.84
2.2
Current year 1.45
Extreme 1.45
2.86
1 year 0.53
Extreme 0.53
2.86
3 years 0.53
Extreme 0.53
29.55
5 years 0.53
Extreme 0.53
2,400
10 years 0.53
Extreme 0.53
8,182.5
Manager TitleAgeSince
Chief Executive Officer 68 2022-10-09
President 48 -
Chief Tech/Sci/R&D Officer - 2025-10-27
Director TitleAgeSince
Chairman 67 2024-02-13
Director/Board Member 55 2018-12-31
Director/Board Member 68 2023-02-01
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Buy

Director

25,000 0.0151%
7/7/26 Buy

Director

30,000 0.0181%
7/7/26 Sell

Chief Executive Officer

-147,064 0.0887%
Change 5-day change 1-year change 3-year change Capi.($)
-1.42%+6.63%+109.00%-93.17% 363M
+0.93%-0.63%+3.89%+14.93% 48.7B
+0.26%+2.93%+439.43%+533.80% 42.05B
-1.53%-2.25%+30.95%+7.15% 38.26B
+0.69%+2.40%+10.48%+63.05% 37.5B
+2.47%+2.63%+14.71%+48.37% 31.44B
-0.47%+1.16%+35.93%+126.09% 16.33B
+2.31%-0.49% - - 16.47B
+0.29%+1.87%+8.17%+18.60% 13.98B
-1.43%-2.63%+3.70%-36.38% 12.43B
Average +0.21%+1.34%+72.92%+75.83% 25.75B
Weighted average by Cap. +0.46%+0.94%+89.17%+120.99%

Financials

2026 *2027 *
Net sales - -
Net income -50.56M -43.88M -41.08M -37.58M -70.95M -4.82B -71.87M -481M -189M -2.41B -190M -186M -8.01B -64.87M -56.29M -52.71M -48.22M -91.03M -6.18B -92.22M -617M -242M -3.09B -244M -238M -10.28B
Net Debt -94.2M -81.75M -76.55M -70.02M -132M -8.97B -134M -896M -351M -4.48B -354M -346M -14.92B -331M -287M -269M -246M -465M -31.55B -471M -3.15B -1.24B -15.76B -1.24B -1.22B -52.47B
Logo Palisade Bio, Inc.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Employees
-
Date Price Change Volume
26-08-06 US$2.090 -1.42% 779,180
26-08-05 US$2.120 +2.42% 1,979,672
26-08-04 US$2.070 +6.70% 1,646,432
26-08-03 US$1.940 +2.37% 1,027,155
26-07-31 US$1.895 -3.32% 1,853,422
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.090USD
Average target price
10.22USD
Spread / Average Target
+389.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PALI Stock